Search
Showing results for "1"
Do you know that the clinical team at Perth Children’s Hospital’s Diabetes Clinic can visit your child’s school to administer glucagon or camp education?
It may only have been a matter of months since Abby Carlon was diagnosed with type 1 diabetes but already the 10-year-old knows more than most about the condition. That’s because she’s always kept an eye out for her little sister Mia who was diagnosed with type 1 diabetes when she was three.
Looking at him now, it’s hard to believe busy one-year-old toddler Kye Gilbert was extremely unwell in Perth Children’s Hospital’s critical care unit with a new diagnosis of type 1 diabetes just a few months ago.
Adolescents and young adults with Type 1 Diabetes are invited to be co-researchers at a summit to help develop the Children’s Diabetes Centre’s new exercise gui
Principal Research Fellow
Iatrogenic hypoglycaemia is one of the main limiting factors in the glycaemic management of diabetes. It causes negative biological, psychological, and social consequences in most people with type 1 diabetes and in many with advanced type 2 diabetes. This chapter explores physiological homeostatic mechanisms that prevent hypoglycaemia through glucose counter-regulation, before discussing specific acquired defects of glucose counter-regulation in diabetes, which provides an insight into risk factors for hypoglycaemia.
Half of the mortality in diabetes is seen in individuals <50 years of age and commonly predicted by the early onset of diabetic kidney disease (DKD). In type 1 diabetes, increased urinary albumin-to-creatinine ratio (uACR) during adolescence defines this risk, but the pathological factors responsible remain unknown.
The presence of pleural plaques on radiologic imaging does not confer additional increase in the risk of lung cancer
The aim of this study was to examine the gene response of white blood cells in severe allergic reactions to identify genes that could be targets to new drugs...
Epidermal Growth Factor Receptor (EGFR) plays a critical role in the development of several cancers. Thus, modulation/inhibition of EGFR activity is an appealing target of developing novel cancer therapeutics.